



BRAWN



90632

To,

Date: 13-08-2018

**BSE Limited,
Floor 25, Phirozee Jeejeebhoy Towers,
Dalal Street,
Mumbai- 400001**

Sub: Outcome of 2nd /2018- 19 Board Meeting and Submission of Un-audited Financial Results for the quarter ended 30.06.2018
Scrip Code: 530207

Dear Sir,

This is to inform you that the 2nd / 2018-19 meeting of the Board of Directors held today i.e., Monday, 13th of August, 2018 commenced at 02:30 P.M and concluded at 06:00 P.M at the Registered Office of the Company situated at 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002, inter alia considered the following:

1. Pursuant to Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulation, 2015, approved the Un- audited Quarterly Financial Results for quarter ended 30th June, 2018. Copy of the results is enclosed herewith as Annexure- I.
2. Limited Review Report on Un- audited Quarterly Financial Results for the quarter ended on 30th June, 2018 obtained from the Statutory Auditor has also been taken on record and copy of the same is enclosed herewith as Annexure- II.
3. Approved the notice of 33rd Annual General Meeting of the Company and the same is scheduled to be held on Saturday, 22nd September, 2018.
4. Recommend the appointment of Director in place of Mrs. Brij Bala Gupta who would retire by rotation at the 33rd Annual General Meeting and being eligible offers herself for reappointment.
5. Recommend to regularize Mr. Subhash Chander as an Independent Director of the Company in ensuing Annual General Meeting of the Company.
6. Recommend to regularize Mrs. Kanta Takkar as an Independent Director of the Company in ensuing Annual General Meeting of the Company.
7. Approved the Director's report of the Company for 33rd Annual General Meeting of the Company.
8. Appointed Secretarial Auditor and Internal Auditor of the Company for the Financial Year 2018- 19.
9. With the permission of Chair, Board has approved Reconstitution of Committees

You are requested to take above on record.

Thanking you,

For **BRAWN BIOTECH LIMITED**


Mamta Surkali
Company Secretary

Encl: As above

BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

...for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462
Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48



BRAWN


ANNEXURE I


| BRAWN BIOTECH LIMITED CIN:L74899DL1985PLC022468 REGD. OFFICE: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 | | | | | |
|--|---|-----------------|-----------------|-----------------|-----------------|
| STATEMENT OF STANDALONE UN- AUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED ON 30th JUNE, 2018 | | | | | |
| Rs. In Lakhs | | | | | |
| Sr. No. | Particulars | Quarter Ended | | Year ended | |
| | | 30.06.2018 | 31.03.2018 | 30.06.2017 | 31.03.2018 |
| | | Un-audited | Audited | Un-audited | Audited |
| 1 | Revenue from operations | | | | |
| | Revenue from operations | 1,356.19 | 1,570.51 | 1,094.34 | 5,578.37 |
| | Other Income | 6.12 | 25.52 | 15.94 | 8.97 |
| | Total Revenue | 1,362.31 | 1,596.03 | 1,110.28 | 5,587.34 |
| 2 | Expenses | | | | |
| a | Cost of material consumed | | - | - | - |
| b | Purchase of stock-in-trade | 1,192.23 | 1,390.75 | 997.46 | 4,882.19 |
| c | Change in inventories of finished goods, work in progress and stock in trade | 7.11 | 8.24 | (2.59) | 2.46 |
| d | Employee Benefit expenses | 57.71 | 83.43 | 51.59 | 298.19 |
| e | Depreciation and amortisation expenses | 0.80 | 0.78 | 0.78 | 3.16 |
| f | Finance Cost | 0.65 | 1.63 | 0.52 | 5.73 |
| g | Other expenses | 50.68 | 79.78 | 37.02 | 199.50 |
| | Total Expenses | 1,309.17 | 1,564.61 | 1,084.78 | 5,391.23 |
| 3 | Profit from Operation before Other Income, exceptional and extraordinary items (1-2) | 53.13 | 31.42 | 25.50 | 196.10 |
| 4 | Other Income | | | | |
| 5 | Profit from ordinary activities before exceptional items (3-4) | 53.13 | 31.42 | 25.50 | 196.10 |
| 6 | Exceptional Items | | | | |
| 7 | Profit from ordinary activities before tax (5-6) | 53.13 | 31.42 | 25.50 | 196.10 |
| 8 | Tax Expenses | 15.84 | 15.32 | 8.72 | 67.94 |
| 9 | Profit (Loss) for the period from continuing operations (7-8) | 37.29 | 16.10 | 16.78 | 128.16 |
| 10 | Profit/(loss) from discontinuing operations | | | | |
| 11 | Tax expense of discontinuing operations | | | | |
| 12 | Profit/(loss) from Discontinuing operations (after tax) (10-11) | | | | |
| 13 | Profit (Loss) for the period (9+12) | 37.29 | 16.10 | 16.78 | 128.16 |
| 14 | Other Comprehensive Income | 3.82 | 0.91 | (0.13) | (2.74) |
| | Total Comprehensive Income | 41.11 | 17.01 | 16.65 | 125.42 |
| 15 | Details of equity share capital | | | | |
| | Paid-up equity share capital | 300.03 | 300.03 | 300.03 | 300.03 |
| | Face value of equity share capital | | | | |
| 16 | Reserve excluding Revaluation Reserve | 504.17 | 463.06 | 354.30 | 463.06 |
| 17 | Earnings per share | | | | |
| i | Basic earnings per share | 1.37 | 0.57 | 0.56 | 4.18 |
| ii | Diluted earnings per share | 1.37 | 0.57 | 0.56 | 4.18 |

NOTES :-

- Results for the quarter ended on 30th June, 2018 were reviewed by the Audit committee and then approved by the Board of Directors at their meeting held on 13th August, 2018.
- Statutory auditors have carried out the limited review of the financial results for the quarter ended 30.06.2018
- The above results have been prepared in compliance with the recognition and measurement principles of the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS), as amended by the Companies (Indian Accounting Standards) (Amendment rules), 2016 prescribed under Section 133 of the companies Act, 2013 and other recognized accounting practices and policies to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- The above Standalone Un- audited Financial Results for the quarter ended on 30.06.2018 are available on company's website www.brawnbiotech.com and BSE website www.bseindia.com.
- Previous year / period figures have been regrouped / rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
For Brawn Biotech Limited


Brij Raj Gupta
Managing Director
DIN NO. 00974969
Date : 13-08-2018
Place: Delhi



BRAWN BIOTECH LTD.

(Formerly Known as Brawn Pharmaceuticals Ltd.)

...for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,
Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462
Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48




BRAWN

| BRAWN BIOTECH LIMITED CIN:L74899DL1985PLC022468 REGD. OFFICE: 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 Extract of Standalone Un- audited Financial Results for the quarter ended on 30th June, 2018 | | | | |
|---|--|---------------|------------|------------|
| Rs. In Lakhs | | | | |
| Sr. No | Particulars | Standalone | | |
| | | Quarter Ended | | Year Ended |
| | | 30.06.2018 | 30.06.2017 | 31.03.2018 |
| | | Un- audited | Unaudited | Audited |
| 1 | Total income from opearion | 1,356.19 | 1,094.34 | 5,587.34 |
| 2 | Net Profit/(Loss) from ordinary activities after tax | 37.29 | 16.78 | 128.16 |
| 3 | Net Profit/(Loss) for the period after tax (after extraordinary items) | 37.29 | 16.78 | 128.16 |
| 4 | Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income] | 41.11 | 16.65 | 125.42 |
| 5 | Equity Share Capital | 300.03 | 300.03 | 300.03 |
| 6 | Reserve (excluding Revaluation Reserves as shown in the balance sheet of previos year) | 504.17 | 354.30 | 463.06 |
| 7 | Earning per share (before extraordinary items)(not annualised): (of rs. 10 each) | | | |
| | (a) Basic (Rs.) | 1.37 | 0.56 | 0.57 |
| | (b) Diluted (Rs.) | 1.37 | 0.56 | 0.57 |
| 8 | Earning per share (after extraordinary items)(not annualised): (of rs. 10 each) | | | |
| | (a) Basic (Rs.) | 1.37 | 0.56 | 0.57 |
| | (b) Diluted (Rs.) | 1.37 | 0.56 | 0.57 |

Notes:

- The above is an extract of the detailed format of Quarterly financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarterly financial results are available on the Stock Exchange website (www.bseindia.com) and on the company's website (www.brawnbiotech.com).
- The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 13.08.2018.
- The Financials has been prepared in accordance with Companies (Indian Accounting Standards) Rules 2015 (Ins-AS) to the extent applicable.
- The Company is engaged primarily in the business of Pharmaceuticals. Accordingly, there is no separate reportable segments as per Ind-AS 108 dealing with Operating Segments.
- Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figures.

For and on behalf of Board
 For Brawn Biotech Limited

 Brj Raj Gupta
 Managing Director
 DIN NO. 00974969

Place: Delhi
Date: 13-08-2018

BRAWN BIOTECH LTD.
 (Formerly Known as Brawn Pharmaceuticals Ltd.)

...for better life

Regd. Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 0124-4666152, 4222462,
 Email: solution@brawnbiotech.com, Website : www.brawnbiotech.com

Export Office : 4B, Asaf Ali Road, II Floor, Delhi Stock Exchange Building, New Delhi 110002 IN Tel: 011-23275208 Fax : 011-23275208

Corporate Office : Plot No. - 30, Sector - 33 , Near Hero Honda Factory, Gurugram (Haryana) 122001 , Tel.: 0124-4666152, 4222462
 Email: solution@brawnbiotech.com

Works : 13, Industrial Area, N.I.T., Faridabad -121001 (Haryana) Tel.: +91 - 8010416849/48



Independent Auditor's Report on Quarterly Standalone Financial Results of BRAWN BIOTECH LIMITED pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015


To,
**The Board of Directors of
Brawn Biotech Limited**

We have reviewed the accompanying statement of Unaudited Financial Results of **Brawn Biotech Limited** (the "Company") for the quarter ended 30th June 2018, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016. This statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on these financial results based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial results are free of material misstatement. A review is limited primarily to inquiries of Company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable Indian Accounting Standards i.e., Ind AS prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No.CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For Rajiv Udai & Associates
Chartered Accountants
Firm Registration No. 18764N**


**Rajeev Jain
(Partner)
(Membership No. 99767)**



**Place:Delhi
Date: 13-08-2018**